Early Detection and Prognostic Assessment of Cutaneous Melanoma Consensus on Optimal Practice and the Role of Gene Expression Profile Testing

被引:16
作者
Kashani-Sabet, Mohammed [1 ]
Leachman, Sancy A. [2 ,3 ]
Stein, Jennifer A. [4 ]
Arbiser, Jack L. [5 ]
Berry, Elizabeth G. [2 ,3 ]
Celebi, Julide T. [4 ]
Curiel-Lewandrowski, Clara [6 ]
Ferris, Laura K. [7 ,8 ]
Grant-Kels, Jane M. [9 ,10 ]
Grossman, Douglas [11 ]
Kulkarni, Rajan P. [2 ,3 ]
Marchetti, Michael A. [12 ]
Nelson, Kelly C. [13 ]
Polsky, David [4 ]
Seiverling, Elizabeth V. [14 ]
Swetter, Susan M. [15 ,16 ]
Tsao, Hensin [17 ,18 ]
Verdieck-Devlaeminck, Alexandra [2 ,3 ]
Wei, Maria L. [19 ,20 ]
Bar, Anna [2 ,3 ]
Bartlett, Edmund K. [12 ]
Bolognia, Jean L. [21 ]
Bowles, Tawnya L. [22 ]
Cha, Kelly B. [23 ]
Chu, Emily Y. [24 ]
Hartman, Rebecca I. [17 ,18 ]
Hawryluk, Elena B. [17 ,18 ]
Jampel, Risa M. [25 ]
Karapetyan, Lilit [26 ]
Kheterpal, Meenal [27 ]
Lawson, David H. [5 ]
Leming, Philip D. [28 ]
Liebman, Tracey N. [4 ]
Ming, Michael E. [24 ]
Sahni, Debjani [29 ]
Savory, Stephanie A. [30 ]
Shaikh, Saba S. [31 ]
Sober, Arthur J. [17 ,18 ]
Sondak, Vernon K. [26 ]
Spaccarelli, Natalie [32 ]
Usatine, Richard P. [33 ]
Venna, Suraj [34 ]
Kirkwood, John M. [7 ,8 ]
机构
[1] Calif Pacific Med Ctr, Ctr Melanoma Res & Treatment, Res Inst, San Francisco, CA USA
[2] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Dermatol, Portland, OR USA
[3] Oregon Hlth & Sci Univ, Knight Canc Inst, Dept Family Med, Portland, OR USA
[4] NYU Langone Hlth, Ronald O Perelman Dept Dermatol, New York, NY USA
[5] Emory Univ, Winship Canc Inst, Atlanta Vet Adm Hlth Ctr, Dept Dermatol,Sch Med, Atlanta, GA USA
[6] Univ Arizona, UA Canc Ctr Skin Canc Inst, Coll Med, Div Dermatol, Tucson, AZ USA
[7] Univ Pittsburgh, UPMC Hillman Canc Ctr, Dept Dermatol, Pittsburgh, PA USA
[8] Univ Pittsburgh, UPMC Hillman Canc Ctr, Dept Med, Pittsburgh, PA USA
[9] Univ Connecticut, Sch Med, Dept Dermatol, Farmington, CT USA
[10] Univ Florida, Dept Dermatol, Coll Med, Gainesville, FL USA
[11] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[12] Mem Sloan Kettering Canc Ctr, Dept Med, Dermatol Serv, New York, NY USA
[13] Univ Texas MD Anderson Canc Ctr, Dept Dermatol, Houston, TX USA
[14] Tufts Univ, Sch Med, Dept Dermatol, Boston, MA USA
[15] Stanford Univ, Med Ctr & Canc Inst, Dept Dermatol, Pigmented Lesion & Melanoma Program, Palo Alto, CA USA
[16] VA Palo Alto Hlth Care Syst, Dermatol Serv, Palo Alto, CA USA
[17] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA USA
[18] Harvard Med Sch, Boston, MA USA
[19] Univ Calif San Francisco, Dermatol Dept, San Francisco, CA USA
[20] San Francisco VA Hlth Care Syst, Dermatol Serv, San Francisco, CA USA
[21] Yale Univ, Sch Med, Dept Dermatol, New Haven, CT USA
[22] Intermt Med Ctr, Murray, UT USA
[23] Michigan Med, Dept Dermatol, Ann Arbor, MI USA
[24] Univ Penn, Dept Dermatol, Philadelphia, PA USA
[25] Univ Maryland, Dept Dermatol, Baltimore, MD USA
[26] H Lee Moffitt Canc Ctr & Res Inst, Dept Cutaneous Oncol, Tampa, FL USA
[27] Duke Univ, Dept Dermatol, Durham, NC USA
[28] Cincinnati Canc Advisors, Cincinnati, OH USA
[29] Boston Med Ctr, Boston, MA USA
[30] Univ Texas Southwestern Med Ctr Dallas, Dept Dermatol, Dallas, TX USA
[31] Fox Chase Canc Ctr, Dept Hematol Oncol, Philadelphia, PA USA
[32] Ohio State Univ, Wexner Med Ctr, Columbus, OH USA
[33] Univ Texas Hlth, San Antonio, TX USA
[34] Univ Virginia, Inova Fairfax Hosp, Inova Schar Canc Inst, Sch Med, Charlottesville, VA USA
关键词
RISK-FACTORS; SKIN-CANCER; METAANALYSIS; DIAGNOSIS;
D O I
10.1001/jamadermatol.2023.0127
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Importance Therapy for advanced melanoma has transformed during the past decade, but early detection and prognostic assessment of cutaneous melanoma (CM) remain paramount goals. Best practices for screening and use of pigmented lesion evaluation tools and gene expression profile (GEP) testing in CM remain to be defined.Objective To provide consensus recommendations on optimal screening practices and prebiopsy diagnostic, postbiopsy diagnostic, and prognostic assessment of CM.Evidence Review Case scenarios were interrogated using a modified Delphi consensus method. Melanoma panelists (n = 60) were invited to vote on hypothetical scenarios via an emailed survey (n = 42), which was followed by a consensus conference (n = 51) that reviewed the literature and the rationale for survey answers. Panelists participated in a follow-up survey for final recommendations on the scenarios (n = 45).Findings The panelists reached consensus (>= 70% agreement) in supporting a risk-stratified approach to melanoma screening in clinical settings and public screening events, screening personnel recommendations (self/partner, primary care provider, general dermatologist, and pigmented lesion expert), screening intervals, and acceptable appointment wait times. Participants also reached consensus that visual and dermoscopic examination are sufficient for evaluation and follow-up of melanocytic skin lesions deemed innocuous. The panelists reached consensus on interpreting reflectance confocal microscopy and some but not all results from epidermal tape stripping, but they did not reach consensus on use of certain pigmented lesion evaluation tools, such as electrical impedance spectroscopy. Regarding GEP scores, the panelists reached consensus that a low-risk prognostic GEP score should not outweigh concerning histologic features when selecting patients to undergo sentinel lymph node biopsy but did not reach consensus on imaging recommendations in the setting of a high-risk prognostic GEP score and low-risk histology and/or negative nodal status.Conclusions and Relevance For this consensus statement, panelists reached consensus on aspects of a risk-stratified approach to melanoma screening and follow-up as well as use of visual examination and dermoscopy. These findings support a practical approach to diagnosing and evaluating CM. Panelists did not reach consensus on a clearly defined role for GEP testing in clinical decision-making, citing the need for additional studies to establish the clinical use of existing GEP assays.
引用
收藏
页码:545 / 553
页数:9
相关论文
共 34 条
  • [11] Meta-analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors
    Gandini, S
    Sera, F
    Cattaruzza, MS
    Pasquini, P
    Zanetti, R
    Masini, C
    Boyle, P
    Melchi, CF
    [J]. EUROPEAN JOURNAL OF CANCER, 2005, 41 (14) : 2040 - 2059
  • [12] Meta-analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi
    Gandini, S
    Sera, F
    Cattaruzza, MS
    Pasquini, P
    Abeni, D
    Boyle, P
    Melchi, CF
    [J]. EUROPEAN JOURNAL OF CANCER, 2005, 41 (01) : 28 - 44
  • [13] Case-Control Study of Tumor Stage-Dependent Outcomes for Cutaneous Squamous Cell Carcinoma in Immunosuppressed and Immunocompetent Patients
    Gonzalez, Jessica L.
    Cunningham, Kiera
    Silverman, Rebecca
    Madan, Elena
    Nguyen, Bichchau Michelle
    [J]. DERMATOLOGIC SURGERY, 2019, 45 (12) : 1467 - 1476
  • [14] Molecular risk prediction in cutaneous melanoma: A meta-analysis of the 31-gene expression profile prognostic test in 1,479 patients
    Greenhaw, Bradley N.
    Covington, Kyle R.
    Kurley, Sarah J.
    Yeniay, Yildiray
    Cao, Nhat Anh
    Plasseraud, Kristen M.
    Cook, Robert W.
    Hsueh, Eddy C.
    Gastman, Brian R.
    Wei, Maria L.
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (03) : 745 - 753
  • [15] Prognostic Gene Expression Profiling in Cutaneous Melanoma Identifying the Knowledge Gaps and Assessing the Clinical Benefit
    Grossman, Douglas
    Okwundu, Nwanneka
    Bartlett, Edmund K.
    Marchetti, Michael A.
    Othus, Megan
    Coit, Daniel G.
    Hartman, Rebecca I.
    Leachman, Sancy A.
    Berry, Elizabeth G.
    Korde, Larissa
    Lee, Sandra J.
    Bar-Eli, Menashe
    Berwick, Marianne
    Bowles, Tawnya
    Buchbinder, Elizabeth I.
    Burton, Elizabeth M.
    Chu, Emily Y.
    Curiel-Lewandrowski, Clara
    Curtis, Julia A.
    Daud, Adil
    Deacon, Dekker C.
    Ferris, Laura K.
    Gershenwald, Jeffrey E.
    Grossmann, Kenneth F.
    Hu-Lieskovan, Siwen
    Hyngstrom, John
    Jeter, Joanne M.
    Judson-Torres, Robert L.
    Kendra, Kari L.
    Kim, Caroline C.
    Kirkwood, John M.
    Lawson, David H.
    Leming, Philip D.
    Long, Georgina V.
    Marghoob, Ashfaq A.
    Mehnert, Janice M.
    Ming, Michael E.
    Nelson, Kelly C.
    Polsky, David
    Scolyer, Richard A.
    Smith, Eric A.
    Sondak, Vernon K.
    Stark, Mitchell S.
    Stein, Jennifer A.
    Thompson, John A.
    Thompson, John F.
    Venna, Suraj S.
    Wei, Maria L.
    Swetter, Susan M.
    [J]. JAMA DERMATOLOGY, 2020, 156 (09) : 1004 - 1011
  • [16] Hamdan Diaddin, 2019, Oncotarget, V10, P4786, DOI 10.18632/oncotarget.27102
  • [17] Modelling the value of risk-stratified skin cancer screening of asymptomatic patients by dermatologists
    Hartman, R. I.
    Xue, Y.
    Singer, S.
    Markossian, T. W.
    Joyce, C.
    Mostaghimi, A.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2020, 183 (03) : 509 - 515
  • [18] Hsu C-C., The Delphi Technique: Making Sense Of Consensus2007
  • [19] Validation of a clinicopathological and gene expression profile model to identify patients with cutaneous melanoma where sentinel lymph node biopsy is unnecessary
    Johansson, I
    Tempel, D.
    Dwarkasing, J. T.
    Rentroia-Pacheco, B.
    Mattsson, J.
    Ny, L.
    Bagge, R. Olofsson
    [J]. EJSO, 2022, 48 (02): : 320 - 325
  • [20] Johnson MM, 2017, MELANOMA MANAG, V4, P13, DOI 10.2217/mmt-2016-0022